Evolving Paradigms in Prostate Cancer: The Integral Role of PSMA PET/CT in Primary Staging and Therapeutic Decision-Making
The incidence of prostate cancer is increasing, with most diagnosed with localized disease. Appropriate staging is crucial to ensure optimal treatments are delivered. As imaging techniques evolve, it is essential oncologists know the evidence for, emerging research in, and potential challenges associated with PMSA PET/CT in de novo localized prostate cancer.
Please visit https://www.redjournal.org/article/S0360-3016(24)03387-X/fulltext to read the related journal article online.
This activity is available from January 12, 2025, through 11:59 p.m. Eastern time on January 11, 2027.
This article is from the February 2025 issue of the International Journal of Radiation Oncology•Biology•Physics (Red Journal).
Target Audience
This course is designed to meet the interest of radiation oncologists, medical oncologists, surgeons, physicists, diagnostic radiologists, radiation therapists and radiation oncology residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the evidence for PSMA PET/CT in staging prostate cancer.
- Describe the benefits and potential challenges of incorporating PSMA PET/CT into prostate cancer management.
- Discuss ongoing research in prostate cancer using PSMA PET/CT.
Sue Yom, MD, PhD, FASTRO is employed by the University of California and receives compensation from Bristol-Myers Squibb, EMD Serono, Nanobiotx and Elsevier as well as ownership/investment in Springer and Up To Date.
The person(s) above served as the developer(s) of this activity. Additionally, ASTRO Education Committee had control over the content of this activity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $49
- Member: $0
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until January 12, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.